Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Company News

With Immunomedics ADC deal, Everest bolsters cancer pipeline

April 29, 2019 8:29 PM UTC

Undeterred by a complete response letter issued by FDA in January for Immunomedics' sacituzumab govitecan, Everest obtained the therapy's rights in several Asian territories, making the antibody-drug conjugate Everest's most advanced oncology asset thus far.

Everest Medicines Ltd. (Boston, Mass.) did adjust its offer following the CRL, maintaining interest in a deal as other bidders were likely wavering, according to Everest President and CFO Ian Woo...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article